glp-1 obesity drug news today sep 30 2025 New oral delivers up to 12% weight loss in 36 weeks The GLP-1 Revolution Continues
Description
Differences between GLP1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) ...
Reduced risk of side effects
Dan McKees proposed fiscal year 2027 budget would remove GLP-1 drugs from Rhode Islands Medicaid formulary for weight loss, saving $6.3 million in general revenue
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
Led by Dr
